- ETST has reported successful results in the testing of its unique Hygee medical device for detecting sexually transmitted infections
- Hygee detects chlamydia and is intended to be sold as an at-home kit
- This puts ETST on track to market Hygee in early 2019 through its established distribution channels in multiple countries
- In the future, Hygee may also be certified for gonorrhea testing
Earth Science Tech, Inc. (OTCQB: ETST), a biotech company, has received good news on the development and performance of its Hygee medical device. Molecular diagnostic assays by Procréa Fertility Laboratories have analyzed samples obtained by Hygee and successfully identified the presence of chlamydia, confirming earlier test results on more than 500 women (http://cnw.fm/zGM8M).
ETST, based in Doral, Florida, is focused on the cannabidiol, pharmaceutical and nutraceutical sectors, as well as the development, through subsidiaries, of medical devices and research. ETST’s goal is to become a world leader in the CBD space.
For the development of Hygee, manufacturing partner Dermagate has already received certification ISO 13485:2013. It opens the way for Hygee’s marketing by early 2019.
In a news release (http://cnw.fm/7EwvM), Michel Aubé, CEO and chief scientific officer of ETST, said, “Hygee is an incredible innovation, and we have partners from many countries waiting to market the device. This is only the beginning of realizing the potential of this unique device, and we look forward to updating our shareholders on our progress.”
Initially, it will be marketed as an at-home testing device for Chlamydia, ETST said, but it added that R&D efforts in progress indicate that Hygee may soon be certified for gonorrhea testing as well.
ETST also develops and markets hemp-based CBD oil products. The company, and the industry at large, would benefit from the signing of the 2018 Farm Bill by year’s end. That legislation has already has been passed by both houses of Congress, and a provision in it legalizes the growing of industrial hemp in the United States (http://cnw.fm/z6XYz).
ETST holds several wholly owned subsidiaries. Cannabis Therapeutics is an emerging biotechnology company. KannaBidioiD manufactures and distributes in the recreational sector. Earth Science Foundation, Inc. is becoming a non-profit and accepts grants and donations to conduct additional studies. Earth Science Pharmaceutical develops medical diagnostic tools and vaccines. It also formed subsidiary Canno Inno Laboratories Inc., a Montreal, Canada-based company that provides ETST with access to government grants.
For more information, visit the company’s website at www.EarthScienceTech.com
More from CannabisNewsWire
About CannabisNewsWire
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
CannabisNewsWire is at the epicenter of the Cannabis Revolution.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.cannabisnewswire.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer
CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com
